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Abstract
Background: The significance of commensal oropharyngeal flora (COF) as a potential cause of ventilator-associated
pneumonia (VAP) is scarcely investigated and consequently unknown. Therefore, the aim of this study was to
explore whether COF may cause VAP.
Methods: Retrospective clinical, microbiological and radiographic analysis of all prospectively collected suspected
VAP cases in which bronchoalveolar lavage fluid exclusively yielded ≥ 104 cfu/ml COF during a 9.5-year period.
Characteristics of 899 recent intensive care unit (ICU) admissions were used as a reference population.
Results: Out of the prospectively collected database containing 159 VAP cases, 23 patients were included. In these
patients, VAP developed after a median of 8 days of mechanical ventilation. The patients faced a prolonged total
ICU length of stay (35 days [P < .001]), hospital length of stay (45 days [P = .001]), and a trend to higher mortality
(39 % vs. 26 %, [P = .158]; standardized mortality ratio 1.26 vs. 0.77, [P = .137]) compared to the reference population.
After clinical, microbiological and radiographic analysis, COF was the most likely cause of respiratory deterioration in
15 patients (9.4 % of all VAP cases) and a possible cause in 2 patients.
Conclusion: Commensal oropharyngeal flora appears to be a potential cause of VAP in limited numbers of ICU
patients as is probably associated with an increased length of stay in both ICU and hospital. As COF-VAP develops
late in the course of ICU admission, it is possibly associated with the immunocompromised status of ICU patients.
Keywords: Ventilator-associated pneumonia, Bronchoalveolar lavage, Commensal oropharyngeal flora, Intensive
care unit, MALDI-TOF-MS
Background
Mechanically ventilated patients are at risk for ventilator-
associated pneumonia (VAP) [1], which is associated with
an increased intensive care unit (ICU) length of stay
(LOS), morbidity and mortality [2–5]. A globally accepted
gold standard for the diagnosis of VAP is lacking [6–8],
with the exception of the new surveillance ventilator-
associated events definitions [9]. Generally recommended
and accepted microbiological diagnostic modalities for
VAP are quantitative specimen collection techniques as
bronchoalveolar lavage (BAL) [10, 11] and protected
specimen brushing obtained bronchoscopically and non-
bronchoscopically. The identification of aerobic oropha-
ryngeal flora in BAL fluid (BALF) cultures is commonly
considered colonization, contamination from the upper
respiratory tract or otherwise regarded clinically irrelevant,
regardless of quantity [11–13].
Authoritative guidelines remain inconclusive regarding
the role of commensal oropharyngeal flora (COF) as a
causative agent in VAP, mainly due to a scarcity of
studies in this research field [14]. However, there is
evidence that COF may cause pulmonary infection,
mostly in immunocompromized patients. Examples are
Streptococcus oralis/mitis in neutropenic patients [15, 16]
and species of the Streptococcus anginosus group in
patients with predisposing factors including cancer,
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alcoholism [17, 18], and cystic fibrosis [19, 20]. Further-
more, aspiration may cause a pneumonia due to both an-
aerobic and/or aerobic oropharyngeal flora [21]. For the
critically ill, several studies demonstrate that the innate
immune response is declined due to several different
mechanisms [22–24]. Therefore, one may hypothesize that
ICU patients are likewise at risk for infections by COF.
This study explores whether COF can be a cause of VAP.
Methods
Setting
The study was conducted at the Maastricht University
Medical Centre, a 715-bed hospital with approximately
30,000 annual admissions, 18 mixed surgical-medical
ICU beds, and 9 post-cardiothoracic surgery beds. Other
elective postoperative patients are rarely admitted, due
to a 24-h post anaesthesia care unit. When technically
possible and safe, a BAL was performed in all mechanic-
ally ventilated patients who met the clinical criteria of
suspected VAP. These criteria include (≥2 of the follow-
ing) a rectal temperature > 38.0 °C or < 35.5 °C, white
blood cell count > 10,000/μl or < 3,000/μl, purulent spu-
tum, and a new, persistent or progressive infiltrate on
chest X-ray [25]. In patients with localized pulmonary le-
sions, the affected region was sampled, whereas in case
of diffuse pulmonary lesions the middle lobe or lingula
was lavaged. The BALF was microbiologically evaluated
within 15 min after it was obtained. Selective oropharyn-
geal decontamination (SOD) is used since December
2010, whereas selective digestive tract decontamination
(SDD) is used since January 2012. The SOD consists of
topical antibiotics (polymyxin E, tobramycin, amphoteri-
cin B) applied to the oropharynx, whereas the SDD con-
sists of oropharyngeal and gastric application of the
same non-absorbable antibiotics along with a four day
course of intravenous cefotaxime. The ethics committee
of the institution, the “Medical Research Ethics Commit-
tee”, approved the study and informed consent was
regarded unnecessary since standard care was provided.
Definitions
Ventilator-associated pneumonia in clinically suspected
cases (for definition, see previous paragraph) was diag-
nosed if subsequent BALF analysis was indicative for
pneumonia: cultures yielding a potentially pathogenic
microorganism [12] ≥ 104 cfu/ml and/or if ≥ 2 % BALF
cells containing intracellular organisms (ICOs) [10, 26].
In a pneumonia suspected case that was admitted from
home less than 3 days prior to diagnosis, community-
acquired pneumonia (CAP) was considered, if this case
had no recent contact with the healthcare system. A
CAP was also considered when the potentially patho-
genic microorganism was very unlikely to be nosocomial
(e.g. Haemophilus influenzae, Mycoplasma spp.) [27].
When a clinical suspected case was admitted in the hos-
pital for more than 3 days and with positive BALF re-
sults, but was not mechanically ventilated for ≥ 48 in the
72 h prior to the pneumonia, hospital-acquired pneumo-
nia (HAP) was diagnosed [14].
Commensal oropharyngeal flora as the cause of VAP
was considered in VAP suspected cases if BALF quanti-
tative cultures revealed COF ≥ 104 cfu/ml without sig-
nificant growth (≥104 cfu/ml) of other potentially
pathogenic microorganisms. Commensal oropharyngeal
flora included (a combination of) the following bacteria:
viridans streptococci, coagulase-negative staphylococci,
Haemophilus spp. (excluding H. influenzae if not
predominant), Moraxella spp. (if not predominant),
Corynebacterium spp., Neisseria spp., Peptostreptococcus
spp., Stomatococcus spp., and Prevotella spp. [28].
Whereas Candida spp. may occasionally cause a pneu-
monia [29], Candida spp. were considered nonpatho-
genic in this study, consistent with previous studies and
guidelines [30–32].
Data collection
From January 2005 until January 2014, all results of
BALF analyses from patients consecutively admitted to
the ICU were prospectively collected. From this data-
base, patients with suspected COF as the cause for VAP
were included in the present study. Cases lacking a
microbiological BAL report were excluded. Retrospect-
ively, the following clinical data were collected or calcu-
lated from the included cases: body temperature, C-
reactive protein (CRP), white blood cell count, antibiotic
administration, ICU length of stay, hospital length of
stay, duration of mechanical ventilation, mortality, acute
physiology and chronic health evaluation (APACHE)-II
score (to calculate standardized mortality ratio [SMR;
observed mortality divided by expected mortality]) [33],
sequential organ failure assessment (SOFA) score (to de-
termine the extent of critical illness) [34, 35], clinical
pulmonary infection score (CPIS; more than 6 points is
indicative of pneumonia) [36], and post-mortem examin-
ation, if available.
Reference population
On the advice of the statistical department a reference
population was used in order to place the results of sus-
pected cases in perspective. Since June 2013, the hospital
participated in the Dutch National Intensive Care Evalu-
ation registry. To experience the possibilities of this
registry, the characteristics of all patients admitted from
June 2013 to April 2014 in the same ICU were extracted
from this database. Post cardiothoracic surgery patients
(44 % of all ICU admissions) were excluded. It should be
realized that a reference population is not a control
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group and interpretation of finding should be performed
in this perspective.
Microbiological data collection
Bronchoalveolar lavage fluids were initially analysed ac-
cording to a highly standardized protocol as described
elsewhere [37]. From each BALF sample, 6 ml was cen-
trifuged (250 g for 10 min), dividing the sample into
cells and supernatant. The supernatant was stored in
tubes of 1 ml at −80 °C. The cells were re-suspended in
6 ml of a mixture of Eagle’s Minimal Essential Medium
with 2 % Dimethyl Sulfoxide and stored in tubes of 1 ml
at −80 °C. Oropharyngeal flora was (formerly) reported
on the basis of classical bacteriological phenotypic iden-
tification tests. In order to confirm and specify these re-
sults, included samples were defrosted and quantitatively
cultured on blood agar, chocolate agar, and MacConkey
agar. The different colony types were identified using
matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF-MS), a rapid and
highly accurate soft ionization technique [38]. Antibiotic
susceptibility was assessed for all separate strains when
quantitative cultures revealed ≥ 104 cfu/ml. Results of
polymerase chain reactions (PCRs) for viruses and
Pneumocystis jirovecii, as well as Grocott’s methenamine
silver staining, were collected from electronic patient
data organisers using SAP. In patients that were both
admitted to the hospital less than 8 days prior to BAL
procedure and that lacked PCR results, PCRs for the
identification of respiratory viruses were performed on
the defrosted BALF. These viruses included influenza
virus A and B, human respiratory syncytial virus, human
metapneumovirus and parainfluenza virus 1–4. Further-
more, results of endotracheal aspirates (ETA) were ana-
lysed, preferably from the day of BAL, otherwise one day
before or after. Endotracheal aspirates were obtained
twice weekly and in case of clinical suspicion of a pul-
monary infection. Samples were immediately microbio-
logically evaluated when obtained during daytime.
Commensal oropharyngeal flora caused ventilator-
associated pneumonia likelihood
Based on the collected clinical, radiographic, and micro-
biological data and subsequent microbiological analyses
made, the likelihood of presence of COF caused VAP
(COF-VAP) was evaluated by 4 researchers (two consult-
ant ICU physicians, one medical microbiologist, one
ICU researcher).
Statistics
Patient characteristics were analysed using descriptive
statistics and presented as the mean ± standard devi-
ation, median including interquartile range, or absolute
numbers and percentages of patients, where applicable.
Demographic and clinical characteristics of the
suspected cases were compared with the reference popu-
lation using the single sample t-test, the paired samples
t-test or the Fisher’s exact test, where appropriate. For
the comparison of the observed and expected mortality,
a Chi-square test was used. A one-way within-subjects
ANOVA was used to analyse the course of the SOFA-
score, body temperature, leukocytes and CRP. Statistical
significance was defined as P < .05. The IBM SPSS Statis-
tics version 20 for Windows (Chicago, IL, USA) was
used for analysis.
Results
The study was conducted between January 2005 and July
2014. During this period, 17,254 patients were admitted
to the ICU, of which 159 individuals met the VAP cri-
teria during the study period. Twenty-three patients
were considered to have COF-VAP (see Fig. 1 for inclu-
sion flow chart). During the defined period, 899 patients
(excluding post cardiothoracic surgery patients) needed
ICU admission and consequently, these patients were in-
cluded in the reference population.
Basic characteristics including clinical findings, BALF
cytological results and outcome of the studied group
and the reference population are presented in Table 1.
Individual results of the analyses are presented in Table 2.
The most common reason for ICU admission was re-
spiratory failure (7/23 [30 %]) followed by multi-trauma
(5/23 [22 %]). The reason for ICU admission of the
study group was more often surgically related compared
to the reference population (13/23 [57 %] vs. 267/899
[30 %], P = .01). Suspected COF-VAP developed after a
Fig. 1 Inclusion flow chart
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median of 8 days of mechanical ventilation. Aspiration
prior to BAL was considered possible in 3 patients. Five
patients were mechanically ventilated for more than
2 days by means of a tracheostomy prior to the sus-
pected VAP.
Clinical parameters
On the day of BAL, mean CPIS revealed 6.4 (standard
deviation 2.4). An increase in mean SOFA score, white
blood cell count, and CRP was observed on the day after
the diagnosis compared to the day of diagnosis (See Fig.
2). After this initial increase, a gradual and persistent de-
crease was observed for all parameters.
Outcome
As shown in Table 1, median hospital LOS and ICU
LOS in the studied group were significantly longer com-
pared to the reference population (64 days vs. 24 days
[P = .001] and 33 vs. 5.7 days [P < .001], respectively).
The SMR in the studied group revealed 1.26 compared
to 0.77 in the reference population (P = .137).
Microbiological results
Overall cytological BAL findings are presented in Table 1
and an individual overview of cytological and microbio-
logical analysis is provided in Table 2. In 21 patients, a
BALF cell count was performed revealing 13 BALF with
more than 50 % polymorphonuclear neutrophils. In 11
BALF, 2 % or more BALF cells contained ICOs. Add-
itionally, the percentage of squamous epithelial cells, an
indicator of oropharyngeal contamination, was less than
1 % in all patients. In 6 patients, BALF could not be re-
trieved from storage and in 3 patients, BALF culture
yielded no growth. These 3 fluid samples were preserved
for 5, 6, and 9 years. In the remaining 14 BALF, MALDI-
TOF-MS was able to identify 1 or more bacterial species.
In 5 patients, bacteria ≥ 104 cfu/ml were identified, of
which 2 types are potential pathogenic pathogens
(Citrobacter koseri 106 cfu/ml and H. influenzae 106 cfu/
ml) and 1 type possibly pathogenic (E. faecalis 2*104 cfu/
ml). In 4 BALF, the presence of exclusively COF according
to the definition was confirmed by MALTI-TOF-MS.
Endotracheal aspirates were obtained from all studied
cases. Rare, moderate and heavy growth of COF was
present in 9, 1, and 4 cases, respectively. Moderate or
heavy growth of COF was present in 2 out of 15 patients
with probably COF-VAP [sensitivity 13 %]). In 6 cases,
moderate or heavy growth of another pathogenic micro-
organism was identified (S. aureus [twice], P. aeruginosa
[twice], H. influenzae [case described above in this
section], and M. morganii). Three cases were eventually
diagnosed with pneumonia caused by the same micro-
organism (positive predictive value 50 %). PCR on BALF
for viral pathogens was performed in 15 patients.







N = 23 N = 899
Age, mean (SD) 55 (16)
Male (%) 16 (70 %) 557 (62 %) .52
Medical history (%)
Cardiac 12 (52 %)
Pulmonary 7 (30 %)
Oncologic 7 (30 %)
Immunocompromised 2 (9 %) 98 (11 %) .85
Indication for ICU admission (%)
Surgical 13 (57 %) 267 (30 %) .01
Non-surgical 10 (43 %) 632 (70 %) .01
ICU admission scores (SD) n = 21
APACHE-II score 19.8 (9.9) 19.1 (8.4) .75
Predicted mortality 31 % (26) 34 % (26) .60
SOFA score 8.1 (3.3)
Characteristics at the day of
diagnosis (SD)
SOFA score 6.9 (3.7)
Body temperature (°C) 38.3 (1.1)
WBC count (109/L) 14.3 (8.4)
CRP (mg/L) 180 (108)
CPIS 6.4 (2.1)
Median days on MV (IQR) 8 (4–19)
Number of BAL fluid cells 6.9*105
(1.7*105)
of which PMNs 60 % (35)
of which containing ICOs 5.1 (6.5)
Outcome
ICU mortality 9 (39 %) 234 (26 %) .16
SMR (SD) 1.26 (0.42) 0.77 (0.04) .14
28-day mortality 3 (13 %)
60-day mortality 6 (26 %)
Median hospital LOS (IQR) 63 (50–146) 23.7
(=mean)
.001
Median ICU LOS (IQR) 33 (13–62) 5.7
(=mean)
.000
Median days on MV (IQR) 34 (17–67)
Median hospital LOS after
diagnosis (IQR)
22 (10–59)
Median ICU LOS after diagnosis
(IQR)
13 (7–55)
If no number is provided, this information was not available in the
Netherlands intensive care evaluation registry. APACHE-II score could not be
calculated in 2 patients due to incomplete admission data
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Table 2 Characteristics, diagnostic results and outcome in suspected cases of commensal oropharyngeal flora caused ventilator-associated pneumonia
Case Sex Admission
indication







Additional characteristics Diagnosis ICU
LOS
Age




















Tracheostomy COF-VAP or 31
77 87.2 P. aeruginosa 2*103, sensitive
to piper/tazob
C. albicans few P. aeruginosa VAP
3 F Abdominal sepsis 8.2 COF 2*105 R. dentocariosa
2*102
S. aureus heavy Piper/tazob
0-2
Nocturnal CPAP for OSAS COF-VAP 60
57 85.6 S. oralis 7*102 Vancomycin
2-9
S. aureus 6*102
4 F Post cardiac arrest 10.8 COF 105 S. constellatus 106 S. milleri heavy Piper/tazob
0-3
Possible aspiration COF-VAP 33
67 34.6 S. milleri 105 S. epidermidus
3*103
Penicillin 3-8
5 M Multi-trauma 2.5 COF 4*104 S. mitis/oralis
5*103





47 91.5 N. mucosa 103
C. sputigena
5*102







23 68.2 S. aureus 103 S. aureus 2*103
E. cloacae 103 S. anginosus 103

































Table 2 Characteristics, diagnostic results and outcome in suspected cases of commensal oropharyngeal flora caused ventilator-associated pneumonia (Continued)
9 M Respiratory failure 1.4 COF 3*104 Specimen storage
lacking










10 M Respiratory failure 0.2 COF 105 No growth C. albicans rare Ciprofloxacin
−14-0
Lobectomy for aspergilloma.
Imposible to wean from MV.
COF-VAP 70a





16 COF 104 L. acidophilus 102 H. influenza few Piper/tazob
0-2
COF-VAP 11
31 95.4 P. melaninogenetica 2*102 Amoxi/clav acid
2-8


















19.6 COF 3*104 S. anginosis 103 COF moderate Piper/tazob
0-8
COF-VAP 63a
71 56.2 S. constellatus 103 C. freundii
moderate
N. mucosa 102
14 M Multi-trauma 3.4 COF 105 E. faecalis 6*102 COF heavy Piper/tazob
0-1
Tracheostomy COF-VAP 62






15 M Respiratory failure NP COF 104 E. faecalis 2*104 COF few Co-trimoxazole
−25 -13
Aids. ADV ct 17. CMV ct 37.
P. jirovecii +. CT-thorax
suggestive for PcP.
PcP CAP, ADV CAP, and/or
E.faecalis VAP
44a




























55 78.0 C. glabrata 4*102 C. albicans Ciprofloxacin
−3-1
C. albicans 2*102 Vancomycin −2-
2
17 F Post abdominal
surgery
0.0 COF 3*104 Specimen storage
lacking
COF few Missing data COF-VAP 13
70 68.0
18 M Post neurological
surgery
1.6 COF 2*104 S. aureus 3*103 S. aureus heavy Piper/tazob ?-0 COF-VAP or S. aureus VAP 17














73 2.8 K. pneumoniae Meropenem −1-
7
20 M Multi-trauma 19.4 COF 104 H. influenza 106 H. influenza heavy Amoxi/clav acid
−5- -4
Possible aspiration H. influenza CAP 62
49 95.0 E. coli 4*103 OF few Piper/tazob
0-5
N. subflava 4*103 S. aureus few Gentamicin 4
21 F Post cardiac arrest 0.0 COF 104 E. faecium 5*103 COF heavy Piper/tazob
0-3
B- cel CLL. PIV-3 ct 19. PIV-3 CAP or E. faecium VAP 22a




Cultures: CNS, E. faecium

















Table 2 Characteristics, diagnostic results and outcome in suspected cases of commensal oropharyngeal flora caused ventilator-associated pneumonia (Continued)
22 F Cerebral
hemorrhage
7.4 COF 104 C. koseri 106 COF heavy Vancomycin
0-2
C. koseri resistant to
vancomycin. Possible
aspiration.
C. koseri VAP 3a
58 85.6 C. glabrata 103




pneumoniae on day 7
(ct 23. IgG +)
M. pneumoniae CAP 11




















Parainfluenza virus-3 (cycle threshold (ct) 19 [infection
likely]) and Cytomegalovirus (ct 37 [probably reactiva-
tion]) were identified, each virus in 1 case. In 1 patient,
Mycoplasma pneumoniae (ct 23 [infection likely]) was
identified by PCR. In 1 case, both BALF Grocott’s stain-
ing and PCR were positive for Pneumocystis jirovecii.
Antibiotic treatment
Data concerning the administered antibiotics were avail-
able in 22 patients. Eleven of these patients (50 %) re-
ceived (broad spectrum) antibiotics in the 72 h prior to
the BAL. Overall, piperacillin/tazobactam was the most
frequently used antibiotic (15/22 [68 %]). Five patients
received inadequate treatment for COF-VAP (See Table 2;
Patients no. 7, 8, 10, 22, and 23) of which 2 had un-
favourable respiratory outcome (patients no. 8 and 10)
and 2 died (patients no. 10 and 22), 47 and 3 days after
the diagnosis, respectively. Of the 17 patients that re-
ceived appropriate COF-VAP treatment, 6 patients died
after a median of 54 days after the diagnosis.
Post mortem examination
In 4 out of the 9 deceased patients, consent for autopsy
was obtained. Pathological evidence of an active pneu-
monia was found in 3 patients in post-mortem examin-
ation, performed at least 22 days after diagnosis. A faecal
peritonitis was observed in the fourth patient, probably
explaining her respiratory deterioration.
Level of certainty of the presence of commensal
oropharyngeal flora ventilator-associated pneumonia
An alternative diagnosis was concerned more likely in 6
patients: Citrobacter koseri VAP, H. influenzae pneumo-
nia, parainfluenza virus-3 CAP or E. faecium HAP,
Mycoplasma pneumoniae CAP (all 4 with clinical signs
of pneumonia), Pneumocystis jirovecii caused CAP (with
CT-thorax suggestive of Pneumocystis pneumonia), and
abdominal sepsis (with clinical signs of an ileus the day
before the patient deceased). Eleven patients received
antibiotics in the three days prior to the (presumed)
VAP, making their culture results more difficult to
Fig. 2 Course of clinical and laboratory parameters. Numbers signify mean values in all commensal oropharyngeal flora caused ventilator-
associated pneumonia suspected cases. *P value < .05 for the increase/decrease of the value as compared to the previous value
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interpret. The cultures in cases number 2 and 18 yielded
≥103 cfu/ml P. aeruginosa and S. aureus, respectively,
under appropriate antibiotic treatment, which cannot
exclude their causative contribution to VAP. Therefore
these 2 cases were considered to have possible COF-
VAP. In the remaining 15 cases (9.4 % of all VAP cases),
no other infection was found and COF-VAP was consid-
ered likely.
Additional findings
Additionally, 3 cases of probable COF-HAP and 1 case
of probable COF-HAP were identified in 8 eligible cases
(see Appendix). Besides the fact that these 4 positive
cases were immunocompromised due to previous used
medication or malignancies, further discussion of this
subgroup is beyond the scope of this article.
Discussion
This large retrospective analysis of a prospectively col-
lected case series revealed 23 patients suspected of
COF-VAP. In 15 patients (9.4 % of all VAP cases), COF-
VAP was the most likely diagnosis.
Previous studies
So far, 1 currently available study investigated the pos-
sible role of COF as the cause of VAP [39]. This French
group retrospectively investigated 29 episodes of VAP
with significant growth of oropharyngeal and cutaneous
commensal microorganisms in BALF and protected
brush specimen derived from 28 immunocompetent pa-
tients. The suspected cases also revealed signs of VAP
including a longer ICU LOS. A panel of 3 experts con-
firmed 14 out of the 29 (48 %) suspected cases as COF-
VAP (corresponding to 3.8 % of their VAP cases),
whereas in the other cases an alternative diagnosis was
considered more likely. The authors concluded that
COF may cause VAP in ICU patients with no known
prior immunodeficiency, that it has similar clinical fea-
tures as VAP, and that patients should be treated with
antibiotics with the probable exception of stable patients
with a high likelihood of an alternative diagnosis [39].
The results of the present study, using more clinical data
and microbiological analyses, are in support of their pre-
liminary findings.
Two decades ago, several small studies revealed the
presence of COF in post-mortem lung biopsy cultures in
previously mechanically ventilated patients [40–42]
(reported incidences varied from 9 % to 57 %, with not
all studies reporting the level of growth), whereas an-
other study found no COF in post-mortem biopsy diag-
nosed VAP cases [43].
Epidemiology
One might perhaps expect a rise in COF-VAP rates after
the introduction of SOD/SDD, as it focusses on the
elimination of Gram negatives as well as the selection of
commensal bacteria [44]. Yet, so far (see Table 2) no
diagnosis of COF-VAP was made after the introduction
of SOD/SDD, whereas the incidence of VAP per 1,000
ventilator days declined from 4.38 ± 1.64 before to 1.64
± 0.43 (P = .007) after the introduction of SOD and SDD
in our clinic [45].
Results of endotracheal aspirates
Whereas ETA and BALF analysis can both be used to
diagnose VAP [14, 30], results of these 2 diagnostic mo-
dalities agree only fairly [46]. Overall, the current results
confirm the poor agreement between BALF and ETA
analyses results.
Re-cultured bronchoalveolar lavage fluid and
identification with matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry
Whereas all 23 BALF samples revealed ≥ 104 cfu/ml
COF at the time of the BAL procedure, the repeated
microbiological examinations on preserved specimen
were frequently not in accordance. The BALF samples
that revealed no growth were similar durations as the
samples that did reveal growth, suggesting that the time
of storage did not cause the disagreement. However,
Neisseria spp., Streptococcus spp. (not S. pyogenes), and
Haemophilus spp. are known with a limited survival on
inanimate surfaces [47], contributing to the absence of
growth on re-culturing despite the correct solvents and
temperature. The lack of significant growth of micro-
organism could have been related to the storage-related
factors, as well as the presence of antibiotics in the sam-
ple before storage. On the other hand, one may doubt if
the C. koserii, H. influenzae, and E. faecalis identified by
MALDI-TOF-MS were true pathogens or that their
presence was caused by contamination before, during, or
after the BALF storage and retrieval.
Matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry was able to identify all strains
that re-grew on any agar plate. Rothia dentocariosa,
Capnocytophaga sputigena, and Lactobacillus acidoph-
ilus are part of COF, although not included in our defin-
ition since these species were not routinely identified
before MALDI-TOF-MS use.
Diagnosis
Although some results are more difficult to interpret
due to previous antibiotic use, identified COF is mostly
susceptible to the antibiotics used, but was nonetheless
still present in significant numbers in BALF. Further-
more, at least 9 patients that were eventually diagnosed
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with COF-VAP did not receive antibiotics prior to BAL.
In 6 patients, an alternative diagnosis was concerned
more likely, although COF as a contributing or the main
cause of VAP can neither be established nor excluded
with certainty. Remarkably, 3 suspected VAP cases actu-
ally had CAP.
Treatment and outcome
Four out of the 15 patients with probable COF-VAP re-
ceived inappropriate antibiotic treatment. The respira-
tory outcome was unfavourable in 2 out of 3 cases that
survived the VAP episode, suggesting that COF-VAP
should be treated appropriately. Commensal oropharyn-
geal flora is generally susceptible to the antibiotics sug-
gested by authoritative guidelines [14].
Entity or fiction?
Although no hard argument can be provided to state
that COF-VAP is an entity, 6 arguments originated from
the present study support that COF indeed may cause
VAP. First, it is plausible from a pathophysiological point
of view. As stated in the introduction section, COF may
behave pathogenic in immunocompromised patients.
Whereas COF-VAP developed after a median of 8 days
of mechanical ventilation, a previously immunocompe-
tent person may already be considered immunocom-
promised after 48 h of ICU admission [24]. Additionally,
many COF-VAP suspected cases revealed positive viral
and fungal PCR, which is also associated with a de-
creased immune status. Finally, COF was able to cause
HAP and CAP in immunocompromised patients. Sec-
ond, scores resulting from generally accepted clinical
scoring systems, as well as laboratory results, indicated a
significant clinical relevance. Third, cytological analysis
of BALF frequently was indicative of a bacterial infec-
tion. Fourth, COF was the most likely cause of VAP in
15 cases and possibly the cause in 2 cases. Fifth, in-
appropriate antibiotic treatment for COF-VAP (n = 4)
was associated with unfavourable respiratory outcome.
Sixth and last, COF-VAP was associated with increased
ICU and hospital LOS including a trend towards in-
creased mortality as compared to a reference population.
Contrariwise, post-mortem examination 4 days after
BAL of one patient revealed no signs of pneumonia, in-
dicative of a false positive BALF analysis. However, at
the time of BAL, this patient presents with an ileus and
abdominal sepsis was the post-mortem diagnosis. Al-
though it is possible that the patient fulfilled all criteria
for performing a BAL due to the extrapulmonary prob-
lems, BAL should thus only be performed in the absence
of an obvious alternative explanation for the patient’s
clinical presentation.
The current study demonstrated a probable associ-
ation between merely significant growth of COF in VAP
suspected patients and worse outcome. Similar to VAP
caused by other microorganisms [2], it remains un-
known whether this association is causal or that COF-
VAP results from critical illness and that the outcome is
therefore unfavourable.
Limitations of the study
There are several limitations to the study. First, due to
the lack of a globally accepted gold standard to diagnose
VAP [7, 8, 11], VAP in clinically suspected patients was
defined as BALF revealing ≥ 2 % ICOs and/or significant
growth (≥ 104 cfu/ml [36]) of a potential pathogenic
microorganism. Second, a limited number of clinical and
microbiological data were irretrievable in a number of
patients. Third, median ICU and hospital LOS of the
suspected cases were compared to mean LOS in a recent
patient population. Since mean ICU and hospital LOS
declined during the studied period (2005–2013), this
comparison may be unfair. However, since the mean
ICU LOS was 8.6 days in 2005, a median ICU LOS of
33 days in the studied period is still significantly higher.
Fourth, enterococci were excluded as a potential cause
for VAP, although these microorganisms may possibly
also cause VAP in the immunocompromised ICU-
patient. Fifth, a reference population is not a control
group. In future studies, a control group should prefera-
bly consist of “regular” VAP cases to demonstrate that
COF behaves like “regular” VAP causative microorgan-
isms. Finally, in the process of BALF storage and re-
culturing the occurrence of contamination cannot be
ruled out.
Future studies
Since COF-VAP has a low overall incidence (15 out of
6500 ICU admissions [0.23 %]) and VAP incidences de-
cline [45, 48], future research should preferably focus on
multi-centre trials. Notwithstanding, when more similar
studies become available, a meta-analysis could empower
the results of Lambotte et al. and the current study.
Conclusions
As COF was identified as the most likely causative agent
in 9.4 % of all VAP episodes, COF is probably an over-
looked cause of VAP. The immunocompromised status
of the ICU patient may contribute to its origination.
Commensal oropharyngeal flora VAP is probably associ-
ated with significant clinical signs of bacterial infection,
a prolonged ICU and hospital LOS, and a trend towards
increased mortality. In the absence of other pulmonary
and non-pulmonary explanations for a patient’s pulmon-
ary deterioration, ICU physicians should perhaps ac-
knowledge this entity and treat it accordingly.
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Table 3 Individual characteristics, diagnostic results and outcome of the suspected cases of commensal oropharyngeal flora caused hospital-acquired pneumonia and
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ADV: Adenovirus; APACHE: Acute physiology and chronic health evaluation;
BAL: Bbronchoalveolar lavage; BAL: Bronchoalveolar lavage fluid;
CAP: Community-acquired pneumonia; CLL: Chronic lymphocytic leukaemia;
CMV: Cytomegalovirus; CNS: Coagulase-negative staphylococcus;
CPAP: Continues positive airway pressure; CPIS: Clinical pulmonary infection
score; CRP: C-reactive protein; ct: Cycle threshold; ETA: Endotracheal aspirate;
F: Female; HAP: Hospital-acquired pneumonia; ICO: Intracellular organism, in
Table, percentage of BAL fluid cells containing intracellular organisms;
ICU: Intensive care unit; IQR: Interquartile range; LOS: Length of stay; M: Male;
MALDI-TOF-MS: Matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry; MV: Mechanical ventilation; NP: Not performed;
OSAS: Obstructive sleep apnoea syndrome; PcP: Pneumocystis pneumonia;
PCR: Polymerase chain reaction; PIV: Parainfluenza virus;
PMN: Polymorphonuclear neutrophils; SD: Standard deviation; SDD: Selective
digestive tract decontamination; SMR: Standardized mortality ratio;
SOD: Selective oropharyngeal decontamination; SOFA: Sequential organ
failure assessment; VAP: Ventilator-associated pneumonia.
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